POST Online Media Lite Edition



 

Editas Medicine appoints Andrew Hirsch to board

Staff Writer |
Cambridge, Mass., USA - Editas Medicine, a genome editing company, announced the appointment of Andrew Hirsch to its board of directors.

Article continues below




Mr. Hirsch will also serve as chairman of the audit committee of the board.

He is currently Chief Financial Officer of Agios Pharmaceuticals.

Mr. Hirsch has more than 20 years of experience in a range of strategic and operating roles in business, including more than 15 years in the biotech industry.

Prior to his current role at Agios, Mr. Hirsch served as president and chief executive officer of BIND Therapeutics.

Earlier in his career, he held various leadership roles at Avila Therapeutics and Biogen.

LATEST 5 MOVES FROM Massachusetts 


What to read next

Editas Medicine appoints John D. Mendlein to board
Editas Medicine appoints two senior managers
Editas Medicine appoints Katrine S. Bosley as CEO